EPTIFIBATIDE INJECTION SOLUTION

Negara: Kanada

Bahasa: Inggris

Sumber: Health Canada

Bahan aktif:

EPTIFIBATIDE

Tersedia dari:

ACCORD HEALTHCARE INC

Kode ATC:

B01AC16

INN (Nama Internasional):

EPTIFIBATIDE

Dosis:

0.75MG

Bentuk farmasi:

SOLUTION

Komposisi:

EPTIFIBATIDE 0.75MG

Rute administrasi :

INTRAVENOUS

Unit dalam paket:

100ML

Jenis Resep:

Prescription

Area terapi:

PLATELET AGGREGATION INHIBITORS

Ringkasan produk:

Active ingredient group (AIG) number: 0137621001; AHFS:

Status otorisasi:

APPROVED

Tanggal Otorisasi:

2016-05-05

Karakteristik produk

PRODUCT MONOGRAPH
Pr
EPTIFIBATIDE INJECTION
(eptifibatide injection)
Intravenous Solution
2 mg/mL bolus Injection
0.75 mg/mL Injection (as infused)
PLATELET AGGREGATION INHIBITOR
Accord Healthcare Inc. Date of Revision:
3535 boul. St. Charles, Suite 704
April 29, 2016
Kirkland, Quebec
H9H 5B9
Canada
Control # 178949
PRODUCT MONOGRAPH
Pr
EPTIFIBATIDE INJECTION
(eptifibatide injection)
PLATELET AGGREGATION INHIBITOR
ACTION AND CLINICAL PHARMACOLOGY
GENERAL: Eptifibatide reversibly inhibits platelet aggregation by
preventing the binding of
fibrinogen, von Willebrand factor and other adhesive ligands to
glycoprotein IIb/IIIa (GP
IIb/IIIa). When administered intravenously, eptifibatide inhibits _ex
vivo _platelet aggregation in a
dose-
and
concentration-dependent
manner.
Platelet
aggregation
inhibition
is
reversible
following cessation of eptifibatide; this is thought to result from
dissociation of eptifibatide
from the platelet receptor.
PHARMACODYNAMICS:
Eptifibatide
inhibits
platelet
aggregation
induced
by
adenosine
diphosphate (ADP) and other agonists in a dose- and
concentration-dependent manner. The
effect of eptifibatide is observed immediately after administration of
a 180 μg/kg intravenous
bolus. When followed by a 2.0 μg/kg/min continuous infusion, this
regimen produces a >80%
inhibition
of
20
μM
ADP-induced
_ex _
_vivo _
platelet
aggregation,
(at
physiologic
calcium
concentrations) in more than 80% of patients, after more than 8 hours
of infusion. Platelet
inhibition was reversed, with a >50% return of platelet function
towards baseline 4 hours after
discontinuation of an infusion of 2.0 μg/kg/min.
The eptifibatide dosing regimen used in the ESPRIT study was similar
to that used in the
PURSUIT study (a 180 μg/kg bolus followed by a 2.0 μg/kg/min
infusion), but added a second
180 μg/kg bolus ten minutes after the first bolus to avoid a
transient decrease in platelet
aggregation inhibition before reaching steady-state with the
continuous 2.0 μg/kg/min infusion.
This dosing regimen is recommended in or